These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

"Medical Journeys" chart a path each step of the ... by 30% -- roughly the impact of lecanemab (Leqembi) or donanemab (Kisunla)-- using data from the Amsterdam Dementia Cohort among amyloid ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

ongoing clinical trial data, and growing healthcare spending. Get Your Free Sample Market Report: How is the Leqembi Market Predicted to Grow in the Forthcoming Years? Looking ahead, the market is ...

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the monthly intravenous (IV) maintenance regimen of Leqembi ® (lecanemab-irmb ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...

The sBLA is based on modeling of observed data from the Phase 2 study (Study ... before and continues after plaque removal. 1,2,3 Only LEQEMBI works to fight AD in two ways: continuously clearing ...

LEQEMBI's approvals in these countries was based on Phase 3 data from Eisai's, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with ...